CGEM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.697

-4.56%

-0.857

+15.77%

-0.807

-24.61%

Estimates Revision

The market is revising Upward the revenue expectations for Cullinan Therapeutics, Inc. (CGEM) for FY2025, with the revenue forecasts being adjusted by 3.59% over the past three months. During the same period, the stock price has changed by 54.61%.

Revenue Estimates for FY2025

Revise Upward

+3.59%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-8.37%

In Past 3 Month

Stock Price

Go Up

+54.61%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast CGEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEM is 28.60 USD with a low forecast of 23.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

23.00

Averages

28.60

High

34.00

Current: 0.000

Low

23.00

Averages

28.60

High

34.00

Wedbush

Robert Driscoll

Outperform

upgrade

$25 -> $34

2025-12-09

Reason

Wedbush

Robert Driscoll

Price Target

$25 -> $34

2025-12-09

upgrade

Outperform

Reason

Wedbush analyst Robert Driscoll raised the firm's price target on Cullinan Therapeutics to $34 from $25 and keeps an Outperform rating on the shares. The firm notes the company presented initial clinical data for FLT3 x CD3 bispecific CLN-049 in patients with relapsed or refractory acute myeloid leukemia. Cullinan noted that all but one CRS events were Grade 1/2, and most occurred at step up dose, with no discontinuations reported.

BTIG

Julian Harrison

Buy

maintain

$32 -> $38

2025-11-24

Reason

BTIG

Julian Harrison

Price Target

$32 -> $38

2025-11-24

maintain

Buy

Reason

BTIG analyst Julian Harrison raised the firm's price target on Cullinan Therapeutics to $38 from $32 and keeps a Buy rating on the shares. The firm recently caught up with Cullinan management, saying it believes CLN-049 is worth a second look ahead of the company's podium presentation on December 8. The firm added CLN-049 into its model, with a 65% probability of success.

H.C. Wainwright

Buy

maintain

$24 -> $26

2025-11-20

Reason

H.C. Wainwright

Price Target

$24 -> $26

2025-11-20

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Cullinan Therapeutics to $26 from $24 and keeps a Buy rating on the shares Cullinan and partner Taiho Oncology announced they have initiated the rolling submission of a New Drug Application to the FDA seeking accelerated approval of zipalertinib for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum-based systemic chemotherapy. The firm, which expects the rolling NDA submission to be completed by Q1 of 2026, is raising its view of the probability of approval for zipalertinib in EGFR ex20ins mutation-positive NSCLC to 90% from 70%.

H.C. Wainwright

initiated

$24

2025-08-21

Reason

H.C. Wainwright

Price Target

$24

2025-08-21

initiated

Reason

H.C. Wainwright assumed coverage of Cullinan Therapeutics with a Buy rating and $24 price target. The company has the option to co-commercialize zipalertinib in the U.S. with Taiho and is also eligible to receive an additional $130M in regulatory milestones in connection with the agreement, the analyst tells investors in a research note. The firm sees several near-term catalysts for the shares.

Stifel

Alex Thompson

initiated

$22

2025-06-11

Reason

Stifel

Alex Thompson

Price Target

$22

2025-06-11

initiated

Reason

Stifel analyst Alex Thompson resumed coverage of Cullinan Therapeutics with a Buy rating and $22 price target, citing a belief that B-cell depletion represents a highly-validated and versatile approach to the treatment of a vast array of autoimmune diseases and that next-gen approaches, including T-Cell Engagers, have the potential to achieve the right balance of depletion, safety, and ease of use to potentially achieve durable disease remissions. The firm views CLN-978 as "a highly-competitive asset in the growing space," the analyst tells investors.

UBS

David Dai

Buy

downgrade

$30 -> $24

2025-05-12

Reason

UBS

David Dai

Price Target

$30 -> $24

2025-05-12

downgrade

Buy

Reason

UBS analyst David Dai lowered the firm's price target on Cullinan Therapeutics to $24 from $30 and keeps a Buy rating on the shares. Cullinan's key program CLN978 is on track for a data readout in the fourth quarter, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Cullinan Therapeutics Inc (CGEM.O) is -3.14, compared to its 5-year average forward P/E of -6.59. For a more detailed relative valuation and DCF analysis to assess Cullinan Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.59

Current PE

-3.14

Overvalued PE

2.23

Undervalued PE

-15.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.76

Current EV/EBITDA

-1.38

Overvalued EV/EBITDA

7.57

Undervalued EV/EBITDA

-17.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

43.69

Current PS

95.66

Overvalued PS

100.98

Undervalued PS

-13.61

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 156.6% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 156.6% over the last month.

Sold

Bought

CGEM News & Events

Events Timeline

No data

News

2.0

2025-12-08Benzinga

Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More

9.0

2025-12-08Globenewswire

Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients

9.0

2025-12-08Newsfilter

Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients

People Also Watch

Frequently Asked Questions

What is Cullinan Therapeutics Inc (CGEM) stock price today?

The current price of CGEM is 10.9 USD — it has decreased -2.15 % in the last trading day.

What is Cullinan Therapeutics Inc (CGEM)'s business?

Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

What is the price predicton of CGEM Stock?

What is Cullinan Therapeutics Inc (CGEM)'s revenue for the last quarter?

Cullinan Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Cullinan Therapeutics Inc (CGEM)'s earnings per share (EPS) for the last quarter?

Cullinan Therapeutics Inc. EPS for the last quarter amounts to -0.86 USD, increased 22.86 % YoY.

What changes have occurred in the market's expectations for Cullinan Therapeutics Inc (CGEM)'s fundamentals?

How many employees does Cullinan Therapeutics Inc (CGEM). have?

Cullinan Therapeutics Inc (CGEM) has 111 emplpoyees as of January 10 2026.

What is Cullinan Therapeutics Inc (CGEM) market cap?

Today CGEM has the market capitalization of 643.93M USD.